Navigation Links
Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement

SEATTLE, April 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced that on April 16, 2008 it received a letter from The NASDAQ Stock Market indicating that for the last 30 consecutive business days the bid price of its common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 4450(a)(5). This notification has no immediate effect on the listing of or the ability to trade CTI's common stock on The NASDAQ Global Market.

In accordance with Marketplace Rule 4450(e)(2), CTI has been provided 180 calendar days, or until October 13, 2008, to regain compliance. The Company will achieve compliance if the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of ten consecutive business days before October 13, 2008. If CTI does not regain compliance by October 13, 2008, it may have the option to transfer its securities to The NASDAQ Capital Market if it can demonstrate as of that date that it meets the criteria for initial listing on this market set forth in Marketplace Rule 4310(c) (other than the bid price requirement). If such application is approved, CTI would have an additional 180 days to regain compliance while on The NASDAQ Capital Market.

CTI intends to actively monitor the bid price for its common stock between now and October 13, 2008, and will consider available options to resolve the deficiency and regain compliance with the NASDAQ minimum closing bid price requirement.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include statements about events or developments that may affect the Company's stock price, the Company's ability to maintain compliance with other listing requirements between now and October 13, 2008; the risk that NASDAQ exercises its discretion to require that the Company maintain a bid price of at least $1.00 per share for a period in excess of 10 days, the risk that in the event the Company is unable to comply with the minimum bid price prior to October 13, 2008, it may not meet the other criteria required to transfer its listing to the NASDAQ Capital Market and other risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filing on Forms 10-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Investors Contact:

Cell Therapeutics, Inc.

Leah Grant

T: 206.282.7100

F: 206.272.4434


Media Contact:

Cell Therapeutics, Inc.

Dan Eramian

T: 206.272.4343

C: 206.854.1200


SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Announces Filing of Form 10-K
2. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
3. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
4. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
5. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
6. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
7. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
8. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
9. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
10. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
11. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  Sorrento Therapeutics, ... developing new treatments for cancer and associated pain, announced ... Officer, will be presenting at the Aegis Capital ... Vegas :Event:Aegis Capital Corporation 2015 Growth ConferenceDate:Friday, ... room, The Encore @ The Wynn in Las ...
(Date:10/8/2015)... MANASSAS, Va. , Oct. 8, 2015  ATCC, ... announces today that it has been selected by The ... provide vital cell lines to academic, pharmaceutical, and biotechnology ... the United States , ... --> the United States , ...
(Date:10/8/2015)... 8, 2015 Celemics, a global pioneer of ... North American market with the establishment of Celemics America, ... Europe , has secured itself in ... methodology and sample preparation for DNA sequencing and genetic ... and somatic genetic testing more accurately, quickly, and cost ...
(Date:10/8/2015)... PORTLAND, Oregon , October 8, 2015 /PRNewswire/ ... . --> Global Biologics and Biosimilars ... added a report "Global Biologics and Biosimilars Industry ... Growth, Analysis and Forecast" is a professional and ... Biosimilars industry . ) , ...
Breaking Biology Technology:
... Merrimack Pharmaceuticals today announced that it will present at the Jefferies 2010 Global Life Sciences Conference ... provide a company overview at 11:00am EDT , Wednesday, June 9, 2010 at ... , , ... , , , ...
... June 1 Diplomat Specialty Pharmacy, the ... launch of Navigator Health Services, an independent division of ... pharmacy industry. The announcement was made by Diplomat Specialty ... who says that Navigator Health Services was formed in ...
... Calif. , June 1 Epeius Biotechnologies Corporation ( ... "Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as ... the ASCO Annual Meeting on June 8, 2010 . The ... Stanford University Medical Center, Palo Alto CA. ...
Cached Biology Technology:
(Date:9/10/2015)... , Sept. 10, 2015 Pursuant ... Clinic Wellness to create an interactive, image-based health ... health and wellness kiosk.  The unique assessment quantifies ... a number that suggests an individual,s biological age ... values as measured by the kiosk. ...
(Date:9/8/2015)... , Sept. 8, 2015   TREW Marketing ... the new survey, Smart Marketing for Engineers TM ... 580 engineering professionals reveals insightful findings about engineers, preferences ... types of content engineers most value and trust, and ... Marketers targeting technical audiences grapple with how to ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... key concern for enterprises, banks, government organizations, telecommunications, ... and numeric keypads were previously being used to ... introduction of two-factor authentication, wherein individuals could gain ... two different components, such as hardware devices and ...
Breaking Biology News(10 mins):
... "We can make you and we can break you." If ... oxide would start something like that. But this song wouldn,t ... of Rice chemist James Tour demonstrates an environmentally friendly way ... version of single-atom-thick graphene expected to find use in all ...
... A novel approach detects genetically abnormal cells in the blood ... in tumor cells and increase in number with the severity ... The University of Texas MD Anderson Cancer Center report in ... patients in the study also had many times the number ...
... A University of Minnesota Medical School research team led ... a novel approach to ease the chronic and acute ... a mouse model of SCD, Gupta and University of ... that exhibited both musculoskeletal pain and temperature sensitivity, symptoms ...
Cached Biology News:
Request Info...
... digests duplex DNA in a 3'-> 5' ... nick, producing stretches of single-stranded DNA. Under ... III proceeds at a uniform rate yielding ... of exonucleolytic excision of deoxyribonucleotides by Exonuclease ...
Mouse monoclonal [HL-37] to HLA DQ1 + HLA DQ3 ( Abpromise for all tested applications)....
Biology Products: